Chen S and Gardner DG |
Liganded vitamin D receptor displays anti-hypertrophic activity in the murine heart. |
2013 |
J. Steroid Biochem. Mol. Biol. |
pmid:22989481
|
El-Khoury JM et al. |
Does Paricalcitol (Zemplar®) interfere with 1,25-dihydroxyvitamin D measurement by liquid chromatography-tandem mass spectrometry assays? |
2013 |
Clin. Chim. Acta |
pmid:23142648
|
Moe SM and Thadhani R |
What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? |
2013 |
Curr. Opin. Nephrol. Hypertens. |
pmid:24100218
|
Havakuk O et al. |
Effect of vitamin D analogues on acute cardiorenal syndrome: a laboratory rat model. |
2013 |
Isr. Med. Assoc. J. |
pmid:24511650
|
de Boer IH et al. |
Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. |
2013 |
Kidney Int. |
pmid:22913981
|
Nigwekar SU and Thadhani RI |
Shining light on vitamin D trials in chronic kidney disease. |
2013 |
Kidney Int. |
pmid:23364588
|
Sánchez-Ãlvarez JE et al. |
Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis. |
2013 |
Nefrologia |
pmid:23364628
|
Wu-Wong JR et al. |
Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats. |
2013 |
Life Sci. |
pmid:23261531
|
Hwang HS et al. |
Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2. |
2013 |
Nephrol. Dial. Transplant. |
pmid:23229926
|
Ong LM et al. |
Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. |
2013 |
Nephrology (Carlton) |
pmid:23311404
|